CPT code 20206 denotes a percutaneous needle muscle biopsy, a minimally invasive surgical diagnostic procedure used to obtain muscle tissue for evaluation of neuromuscular disease, infection, inflammatory conditions, or metabolic disorders. This code is relevant nationally for both clinical diagnosis and procedural billing, affecting reimbursement workflows across major public and private payers.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of the code’s clinical context, typical sites of service, and the common billing modifiers associated with this procedure. The publication outlines benchmarks relevant to utilization and reimbursement, highlights policy or coding updates that affect claim adjudication, and summarizes documentation elements that support medical necessity.

Intended for coding professionals, billing managers, and clinical leaders, the summary provides actionable clarity on where CPT code 20206 fits in procedural coding hierarchies, common billing practices, and areas where payer policies commonly vary. Data not available in the input is noted where applicable.